Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
bởiStephen Padilla
The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
bởiStephen Padilla
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.







